Randomized Trialhigh evidence
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
JAMA·August 29, 2026·PMID 42666092
Why it mattersEarly PCSK9 inhibition in acute MI achieves rapid and sustained LDL-C lowering, but this trial found no reduction in clinical events within the first year, suggesting that the benefit of aggressive lipid lowering may require longer follow-up or that acute pleiotropic effects are limited.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled